TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07102342: This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients

Sponsor: iRegene Therapeutics Co., Ltd. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,553,600

Rescue Site Savings

+$6,958,780

Unlock Full NCT07102342 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07102342 Rescue Dossier →